Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ligelizumab - IgE inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03580369 Pearl 1 (CQGE031C2302) Chronic spontaneous urticaria Phase 3 1050 Absolute change from baseline in UAS7 (Urticaria Activity Score) at week 12 Ligelizumab dose A q4w for 52 weeks Ligelizumab dose B q4w for 52 weeks Omalizumab 300 mg q4w for 52 weeks Placebo q4w from randomization to wk20, then ligelizumab dose B from wk24 to wk52 Adolescents and adults with chronic spontaneous urticaria inadequately controlled with H1-antihistamines H2-2021 (Q4/2021-Q1/2022 potential COVID impact) Past publications: Study design presented at UCARE 2018 Congress: primary results EADV 2022 (H2 2022) or AAAAI 2023 Manuscript: primary results, Journal (TBD), 2023 NCT04210843 (CQGE031C2302E1) Chronic spontaneous urticaria Phase 3 800 The proportion of subjects with well-controlled disease (UAS7 ? 6) at week 12 Ligelizumab Dose 1 and 3 Ligelizumab Dose 2 and 3 Patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 2026 Study design presented at 2020 EAACI 83 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation